What happened with PODD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Insulet serves people with diabetes who need insulin. Its Omnipod system uses a disposable Pod that sticks to the body and delivers insulin continuously, without external pump tubing or multiple daily injections. Users regularly replace the Pod, creating repeat product sales. Omnipod accounts for the vast majority of the company’s revenue. Omnipod 5 also receives glucose readings from a separately sold monitor and automatically adjusts insulin delivery.
Most sales reach users through wholesalers and other intermediaries, and a small group of distributors accounts for most of Insulet’s revenue. In the United States, commercial insurers and government healthcare programs generally cover users’ Omnipod purchases. Overseas, Insulet or its partners arrange reimbursement with local healthcare systems. The business depends on retaining users, reaching new ones and maintaining coverage and reimbursement terms that support access.
Omnipod 5 relies on agreements with Dexcom and Abbott to connect with their glucose sensors; losing those rights could interrupt product availability unless Insulet completes replacement development and regulatory work. Insulet also needs regulatory clearance before marketing new devices or significant changes in the United States, and it cannot promote unapproved uses.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Tandem Diabetes Care’s t:slim X2 and Mobi insulin pumps compete with Insulet’s Omnipod for insulin-dependent patients and reimbursement. Watch Tandem’s expansion into people with type 2 diabetes requiring intensive insulin therapy, a customer group Omnipod 5 also serves in U.S. adults.
MiniMed Group’s automated insulin pumps and smart insulin pens compete with Insulet’s Omnipod for people requiring intensive insulin therapy. Watch its planned MiniMed Fit patch pump, which would bring that competition closer to Omnipod’s wearable format.
Dexcom sells patients the glucose sensors that feed readings to Insulet’s Omnipod 5, linking both businesses to adoption of automated insulin delivery. Watch G7 compatibility rollouts: Omnipod 5 added it to its U.S. iOS app and in Germany, Sweden, Denmark, Finland and Italy in 2025.
Beta Bionics sells its iLet automated insulin pump to U.S. patients who could instead choose Insulet’s Omnipod, with orders typically paid by third-party payors directly or through distributors. Watch uptake among adults and children aged six and older with type 1 diabetes, where iLet offers dosing without carbohydrate counting.
Abbott sells patients FreeStyle Libre 2 Plus glucose sensors that work with Insulet’s Omnipod 5, tying its diabetes business to wider use of sensor-enabled insulin delivery. Watch the planned Libre 3 Plus integration; Libre 2 Plus compatibility launched in Australia in 2025.
Medtronic’s Diabetes Business sells insulin pumps and replacement supplies for people with type 1 and type 2 diabetes, making it an established rival to Insulet’s Omnipod. Watch its pump improvements and pricing: Insulet warns that competing products gaining acceptance among doctors, patients or payors could pressure its sales and prices.
Abbott Laboratories earningsABT
Abbott's report will show whether demand in its diabetes business is changing, offering a signal about the sensor market that Omnipod 5 relies on.
Read Abbott's diabetes-business trend as a broad signal, not as a direct measure of Libre-compatible sensor sales or Omnipod use. Growth would support the wider sensor-demand backdrop, but would not prove Libre users are choosing Omnipod; a slowdown would make that signal less supportive for Insulet.
Fed Interest Rate Decision
Insulet’s rate decision matters because it can shift borrowing costs across the economy and raise or lower the interest it pays on its SOFR-linked Term Loan B and any revolver borrowings.
Expected4.0%Last release4.0%
If it comes in above expectations
If rates across the economy rise, Insulet could pay more interest on its SOFR-linked Term Loan B and any revolver borrowings, leaving less cash for operations and investment.
If it comes in below expectations
If rates across the economy fall, Insulet could pay less interest on its SOFR-linked Term Loan B and any revolver borrowings, leaving more cash for operations and investment.
Insulet Corporation earningsThis company
Insulet's report will show whether Omnipod sales can keep growing without expansion costs eroding gross margin.
Read U.S. and international Omnipod sales growth alongside gross margin, keeping currency effects in mind for international sales. Growth in both markets with a steady or rising margin would show demand turning into sales without a clear loss of manufacturing efficiency; slower growth or a falling margin would point to access, demand or production costs failing to keep pace.
MiniMed Group, Inc. earningsMMED
MiniMed Group's report will show how its insulin-pump business is progressing and whether its planned Fit patch pump is moving closer to Omnipod's wearable format.
Read MiniMed Group's pump-business sales alongside any update on the planned Fit patch pump. Stronger sales and progress on Fit would mean more direct competition for Insulet in wearable insulin delivery; weaker sales or stalled progress would mean less evidence that this added competitive pressure is building.
